P-008

P-008 is a pharmaceutical candidate under development by Pangea Pharmaceuticals for the treatment of gallstone disease. Pangea Pharmaceuticals is a specialty pharmaceutical company that primarily focuses on the development of reformulated or generic versions of existing drugs, often utilizing the 505(b)(2) regulatory pathway. While specific details regarding the active ingredient or molecular target of P-008 have not been publicly disclosed, drugs in this therapeutic category typically involve bile acid analogs, such as ursodeoxycholic acid, which work by decreasing the cholesterol content of bile and facilitating the dissolution of cholesterol-rich gallstones. The product is part of Pangea's internal pipeline of candidates aimed at addressing established medical needs with improved pharmaceutical formulations.